Management of Chronic Hepatic Itch

Area of Science:

• Hepatology
• Gastroenterology
• Clinical Medicine

Background:

• Hepatic itch (pruritus) is a debilitating symptom in various liver diseases, especially cholestatic conditions.
• It occurs independently of liver disease severity or cholestasis extent.
• Standard antihistamines are ineffective for managing hepatic itch.

Purpose of the Study:

• To outline current therapeutic strategies for hepatic itch in liver disease.
• To discuss the efficacy of established and emerging treatments.
• To provide guidance on managing refractory pruritus.

Main Methods:

• Review of current clinical guidelines and literature on hepatic itch management.
• Stepwise therapeutic approach including cholestyramine, rifampicin, naltrexone, and sertraline.
• Consideration of novel agents and interventional procedures.

Main Results:

• A guideline-based stepwise treatment algorithm is recommended.
• Anion exchange resins (cholestyramine) are first-line therapy.
• Second-line options include rifampicin, naltrexone, and sertraline.

Conclusions:

• Hepatic itch requires a structured, stepwise treatment approach.
• Emerging therapies like bezafibrate and ileal bile acid transporter inhibitors show promise.
• Refractory cases may necessitate experimental or invasive interventions.